Diabetes management is all about timely insights. That’s where HbA1c comes in. By reflecting average blood glucose levels over the past 2–3 months, HbA1c offers clinicians a clear window into a patient’s long-term glycaemic control.

A normal HbA1c level for individuals without diabetes is below 5.7% (<39 – 40 mmol/mol). A range of 5.7% to 6.4% (42 – 47 mmol/mol) indicates prediabetes. While ≥6.5% (48 mmol/mol) or higher generally indicates diabetes. For those with diabetes, a common target is often below 7%.

Traditionally used for diagnosis - identifying diabetes at ≥6.5% HbA1c and ongoing management, it’s an essential tool for monitoring treatment effectiveness and preventing complications such as cardiovascular disease, neuropathy, and retinopathy.

But what if clinicians could get accurate HbA1c results in minutes, right at the point of care?

This immunofluorescence-based POCT analyser delivers quantitative HbA1c results from just 5 µL of blood in ~5 minutes, making same-visit clinical decisions possible.

Why FIAPro matters:

* Rapid results enable immediate clinical action

* Accurate, automated readings reduce human error

* Supports better patient outcomes through timely interventions

* Clinical speed and simplicity: Designed for POC environments, the analyser is CE-marked, easy to use, and suitable for rapid testing where minutes matter.

* Connectivity and workflow integration: Android-based interface with built-in connectivity options (e.g., LIS/HIS), facilitating seamless data flow into patient records.

* Adaptable platform: While HbA1c is a critical test, the system’s flexibility also supports other markers of cardiovascular risk and systemic disease like hs-cTnI, D-Dimer and CRP enabling multiparameter diagnostics at the point of care.

With FIAPro, healthcare providers can diagnose, monitor, and manage diabetes faster and smarter, enhancing patient care while streamlining operations.

Further Information:

For enquiries regarding the FIAPro™ Immunofluorescence Analyser, including assay availability, technical specifications, governance documentation, or discussions with POCT and pathology teams, please email: info@sussexbiologicals.co.uk